Kurs
+1,18%
Likviditet
4,31 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-26 | 08:00 | Bokslutskommuniké 2025 |
2025-11-27 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-28 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-30 | N/A | X-dag ordinarie utdelning SANION 0.00 SEK |
2025-05-28 | N/A | Årsstämma |
2025-05-28 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-27 | - | Bokslutskommuniké 2024 |
2024-11-28 | - | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-05-29 | - | Kvartalsrapport 2024-Q1 |
2024-05-27 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2024-05-25 | - | Årsstämma |
2024-02-29 | - | Bokslutskommuniké 2023 |
2024-01-16 | - | Extra Bolagsstämma 2024 |
2023-11-30 | - | Kvartalsrapport 2023-Q3 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-05-25 | - | Årsstämma |
2023-05-25 | - | Kvartalsrapport 2023-Q1 |
2023-05-24 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2023-02-23 | - | Bokslutskommuniké 2022 |
2022-11-17 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-08-18 | - | Extra Bolagsstämma 2022 |
2022-05-27 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2022-05-25 | - | Årsstämma |
2022-05-25 | - | Kvartalsrapport 2022-Q1 |
2022-02-24 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | Kvartalsrapport 2021-Q3 |
2021-09-16 | - | Extra Bolagsstämma 2021 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-27 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2021-05-26 | - | Årsstämma |
2021-05-26 | - | Kvartalsrapport 2021-Q1 |
2021-03-17 | - | Bokslutskommuniké 2020 |
2020-11-30 | - | Kvartalsrapport 2020-Q3 |
2020-10-23 | - | Extra Bolagsstämma 2020 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-05-28 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2020-05-06 | - | Årsstämma |
2020-05-06 | - | Kvartalsrapport 2020-Q1 |
2020-02-07 | - | Extra Bolagsstämma 2019 |
2020-02-07 | - | Bokslutskommuniké 2019 |
2019-11-13 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-05-31 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2019-05-29 | - | Årsstämma |
2019-05-29 | - | Kvartalsrapport 2019-Q1 |
2019-02-21 | - | Bokslutskommuniké 2018 |
2018-11-14 | - | Kvartalsrapport 2018-Q3 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-25 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2018-05-24 | - | Årsstämma |
2018-05-24 | - | Kvartalsrapport 2018-Q1 |
2018-02-21 | - | Bokslutskommuniké 2017 |
2018-01-19 | - | Extra Bolagsstämma 2018 |
2017-11-15 | - | Kvartalsrapport 2017-Q3 |
2017-08-23 | - | Kvartalsrapport 2017-Q2 |
2017-05-24 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2017-05-23 | - | Årsstämma |
2017-05-11 | - | Kvartalsrapport 2017-Q1 |
2017-02-21 | - | Bokslutskommuniké 2016 |
2016-10-13 | - | Extra Bolagsstämma 2016 |
2016-05-11 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2016-05-10 | - | Årsstämma |
2016-05-10 | - | Kvartalsrapport 2016-Q1 |
2016-02-19 | - | Bokslutskommuniké 2015 |
2015-11-20 | - | Kvartalsrapport 2015-Q3 |
2015-09-04 | - | Extra Bolagsstämma 2015 |
2015-08-31 | - | Kvartalsrapport 2015-Q2 |
2015-05-21 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
2015-05-20 | - | Årsstämma |
2015-05-20 | - | Kvartalsrapport 2015-Q1 |
2015-02-20 | - | Bokslutskommuniké 2014 |
2014-11-21 | - | Kvartalsrapport 2014-Q3 |
2014-08-22 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
Land | Danmark |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the ongoing ion channel research collaboration with Boehringer Ingelheim has been extended with one year.
“The program is currently in the lead optimization stage following the successful research milestone in October 2024. We look forward to continuing our partnership with Boehringer Ingelheim scientists in developing a potentially first-in-class therapeutic approach aimed at addressing cognitive impairment associated with schizophrenia, an aspect of the disease that severely impacts patients' daily lives”, said Karin Sandager, CSO of Saniona.
Saniona and Boehringer Ingelheim entered the ongoing research collaboration in 2020, aiming to discover new treatments for schizophrenia by targeting a CNS ion channel. Under the agreement, Boehringer Ingelheim holds exclusive worldwide rights to research, develop, manufacture, and commercialize the therapeutics resulting from the collaboration. Saniona is eligible to receive up to €76.5 million in milestone payments, as well as royalties on worldwide net sales.
For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona’s partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.